Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.

Also called NCT02010242

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 136 participants (enrolled count) (from the registry)
Sponsor
Asahi Kasei Therapeutics, AB (from the registry)
Registry
  • NCT NCT02010242
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Czechia, Germany, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02010242. Randomized; quadruple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2025-02-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
Condition
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Intervention (Drug)
GKT137831
Intervention (Drug)
Placebo
Lead sponsor
Asahi Kasei Therapeutics, AB (class: industry)

Record details

Record id
cardio:ct-nct02010242
Content hash
679df41ed2a5f1b4e2b9df5cdb0af8485c2bebc4e13b9fcb1521712ecbfd1328